Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025
| MDWD Stock | USD 19.83 1.55 8.48% |
About 54% of Mediwound's shareholders are presently thinking to get in. The analysis of overall sentiment of trading Mediwound stock suggests that some investors are interested at this time. The current market sentiment, together with Mediwound's historical and current headlines, can help investors time the market. In addition, many technical investors use Mediwound stock news signals to limit their universe of possible portfolio assets.
Mediwound |
CAMBRIDGE, Mass., Jan. 08, 2025 -- Vericel Corporation , a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference at 1030 a.m. ET on Wednesday, January 15, 2025. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at httpinvestors.vcel.com. About Vericel Cor
Read at finance.yahoo.com
 |
Mediwound Fundamental Analysis
We analyze Mediwound's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mediwound using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mediwound based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Mediwound is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Mediwound Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Mediwound stock to make a market-neutral strategy. Peer analysis of Mediwound could also be used in its relative valuation, which is a method of valuing Mediwound by comparing valuation metrics with similar companies.
Peers
Mediwound Related Equities
| LYEL | Lyell Immunopharma | 5.17 | ||||
| STRO | Sutro Biopharma | 3.05 | ||||
| VCYT | Veracyte | 2.37 | ||||
| MRUS | Merus BV | 1.18 | ||||
| AVTE | Aerovate Therapeutics | 1.17 | ||||
| INBX | Inhibrx | 0.46 | ||||
| GLUE | Monte Rosa | 0.36 | ||||
| SWTX | SpringWorks Therapeutics | 0.06 | ||||
| OCUL | Ocular Therapeutix | 0.13 | ||||
| CRNX | Crinetics Pharmaceuticals | 1.05 | ||||
| SNDX | Syndax Pharmaceuticals | 1.11 | ||||
| REPL | Replimune | 1.16 | ||||
| DYAI | Dyadic International | 1.28 | ||||
| KROS | Keros Therapeutics | 1.50 | ||||
| RNA | Avidity Biosciences | 1.53 | ||||
| NKTX | Nkarta | 1.58 | ||||
| GBIO | Generation Bio | 2.08 | ||||
| KRON | Kronos Bio | 2.80 | ||||
| MLYS | Mineralys Therapeutics, | 2.83 | ||||
| SANA | Sana Biotechnology | 3.15 | ||||
| FHTX | Foghorn Therapeutics | 7.31 |
Complementary Tools for Mediwound Stock analysis
When running Mediwound's price analysis, check to measure Mediwound's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mediwound is operating at the current time. Most of Mediwound's value examination focuses on studying past and present price action to predict the probability of Mediwound's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mediwound's price. Additionally, you may evaluate how the addition of Mediwound to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |